The Cardio-Oncology Surveillance Cascade, Explained (For Primary Care)
How to build an anthracycline / chest-radiation surveillance schedule you can actually run in a 20-minute primary care slot — echo cadence, lipid targets, and when to escalate.
For a primary care clinician inheriting a cancer survivor, the cardio-oncology surveillance schedule is usually the first thing that needs to be reconstructed — and the first thing that quietly slips. Here is a 20-minute-visit-friendly cascade based on NCCN, ASCO, and COG-LTFU primary guidance.
The three exposures that drive the cascade
Cumulative anthracycline dose (doxorubicin-equivalent, mg/m²), radiation field that included the heart, and trastuzumab or other targeted cardiotoxins. Ask the patient for the numbers, not just the drug names — the interval math depends on dose, not the fact of exposure.
Baseline and interval echocardiography
For higher-risk survivors (higher cumulative anthracycline dose, radiation, or both), the working consensus is a baseline echo at entry to long-term follow-up and repeat imaging every 2–5 years, tightened for symptoms or new pregnancy planning. Global longitudinal strain, where available, adds sensitivity for subclinical dysfunction.
Modifiable-risk co-management
Every cardio-onc surveillance visit is also a hypertension, dyslipidemia, glucose, and tobacco visit — the cardiotoxic exposure is the accelerator; blood pressure and lipids are the fuel. Documenting an LDL target and a BP target in the same note as the surveillance interval keeps the plan from drifting.
When to escalate
New dyspnea on exertion, resting tachycardia, orthopnea, or unexplained weight gain in a survivor with anthracycline or chest-radiation history warrants urgent echo and a same-week cardio-oncology referral. Do not wait for the surveillance interval.